Shukra Pharmaceuticals touches roof on executing service agreement with APITCO
Shukra Pharmaceuticals is locked its upper circuit at Rs. 19.91, up by 0.39 points or 2.00% from its previous closing of Rs. 19.52 on the BSE.
The scrip opened at Rs. 19.16 and has touched a high and low of Rs. 19.91 and Rs. 19.16 respectively. So far 549899 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 1 has touched a 52 week high of Rs. 27.15 on 05-Mar-2025 and a 52 week low of Rs. 5.75 on 21-Nov-2024.
Last one week high and low of the scrip stood at Rs. 21.14 and Rs. 19.16 respectively. The current market cap of the company is Rs. 871.82 crore.
The promoters holding in the company stood at 50.96%, while Institutions and Non-Institutions held 0.11% and 48.93% respectively.
Shukra Pharmaceuticals has executed the service agreement with APITCO. The agreement aims to collaborate on various Healthcare Government assignments across sectors, leveraging APITCO's expertise as a PSU and the company's capabilities in healthcare project management, services, and training. This collaboration aims to contribute meaningfully to national-level developmental, industrial, and consulting initiatives.
The company will operate as a business associate / healthcare project management consultant / service & training provider for various healthcare government assignments. All projects undertaken through this collaboration will be executed under defined service level agreements (SLAs) with detailed scope, timelines, deliverables, and performance standards.
Shukra Pharmaceuticals is an ambitious organisation with a deep-rooted focus on sustainability with its impressive range of solutions.
